2015-02-09T12:03:23-07:00 2014-06-30 990 2013-07-01 730580274 OKLAHOMA MEDICAL RESEARCH FOUNDATION OKLA 4052717421 825 NE 13th Street Oklahoma City OK 73104 Tim Hassen Chief Financial Officer 4052717421 2015-02-09 2013 2016-03-07 17:11:31Z Tim Hassen VP and CFO 825 NE 13th Street Oklahoma City OK 73104 70605875 0 X www.omrf.org X 1946 OK OMRF is dedicated to developing a better understanding of and more effective treatments for human disease. 76 76 520 0 0 0 51804565 55978368 3091109 5774897 3003873 3026034 3511838 4688610 61411385 69467909 0 0 0 0 32664419 33893582 0 0 1885769 34817797 37667116 67482216 71560698 -6070831 -2092789 379496939 401849018 61935982 61913600 317560957 339935418 OMRF is dedicated to developing a better understanding of and more effective treatments for human disease. 0 0 19004042 0 16547508 Arthritis & Clinical Immunology/Clinical Operations - The National Institutes of Health once again designated OMRF an Autoimmunity Center of Excellence. With this renewed federal designation came a five-year grant to fund research on lupus and other autoimmune diseases. OMRF joins academic medical centers such as Harvard and Stanford as one of only 10 sites to earn the ACE designation. In 2014, OMRF's scientists continued to make key advances in the understanding and treatment of lupus, rheumatoid arthritis and multiple sclerosis, conditions in which the body mistakenly turns the weapons of the immune system. Among the discoveries this past year were new ways to predict and prevent lupus flares and links between vitamin D and autoimmune disease. The Lupus Foundation of America capped the year by presenting OMRF's Eliza Chakravarty, M.D., with its Mary Betty Stevens Young Investigator Prize. Awarded annually to a researcher who has produced extraordinary achievements in lupus research, the prize was given to Dr. Chakravarty for her work with pregnant mothers suffering from lupus. This prize underscored the strength in autoimmune disease research OMRF has built by supporting laboratory research with clinical studies and patient treatment. 5882740 0 7207222 Cardiovascular Biology Research Program - OMRF scientists explored how suppressing epsins, a family of proteins involved in the creation of new blood vessels, can help stop atherosclerosis, the process of fatty plaques accumulating in the arteries. Atherosclerosis of the coronary arteries is the top killer of both men and women in the United States. On the strength of that work, OMRF secured a new research grant, which its scientists will use to look for more evidence that suppressing epsins can prevent or reverse atherosclerosis. Ultimately, says project leader Hong Chen, Ph.D., "The goal is to find new treatments for atherosclerosis, and we think digging deep into the precise mechanisms of epsins will lead us to them." 4126656 0 4054358 Immunobiology and Cancer Research Program - OMRF recruited an internationally recognized husband-and-wife research team to build its initiatives in breast cancer. Alana Welm, Ph.D., and Bryan Welm, Ph.D., came to OMRF in 2014 from the University of Utah's Huntsman Cancer Institute. Both scientists are keenly interested in precision medicine, which uses genetic information to tailor treatments for individual cancer patients. Specifically, the Welms have done pioneering work in the field of xenografts, which involves transplanting human tumors into laboratory models to study cancer development. "By implanting a patient's tumor in a model, we can help predict if it will be a recurring cancer and, if so, what combination of therapies will be the safest and most effective for the patient," Alana Welm says. "Right now, about 30 percent of breast cancers become fatal. We want to improve those odds." The Welms have already formed collaborations with physicians at the University of Oklahoma's Stephenson Cancer Center, where they are slated to begin a pair of clinical trials in breast cancer. These new trials will give Oklahoma cancer patients access to novel therapeutic approaches available nowhere else. 35882771 0 9353524 Other Program Services 35882771 0 9353524 64896209 1 1 0 1 0 0 0 0 0 1 1 0 0 1 1 1 1 0 0 0 0 0 0 0 1 0 0 0 0 1 1 0 0 0 0 0 0 0 1 1 1 1 0 0 0 0 0 0 0 0 1 136 0 1 520 1 0 0 0 0 1 1 1 1 1 1 0 0 1 1 0 X 76 76 1 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 OK X X X Tim Hassen 4052717421 825 NE 13th Street Oklahoma City OK 73104 Allen Greg S Board Member 1 0 X 0 0 0 Anoatubby Bill Board member 1 0 X 0 0 0 Bass Jim Board Member 1 0 X 0 0 0 Bell Sharon Board Member 1 0 X 0 0 0 Benbrook Bruce Board Member 1 0 X 0 0 0 Benham Lance Board Member 1 0 X 0 0 0 Boghetich Jil Board Member 1 0 X 0 0 0 Braught Barbara Board Member 1 0 X 0 0 0 Burgess Bill Board Member 1 0 X 0 0 0 Brown Randy Board Member 1 0 X 0 0 0 Burgess Ellen Board Member 1 0 X 0 0 0 Cameron Bill Board Member 1 0 X 0 0 0 Carolina Mike Board Member 1 0 X 0 0 0 Carroll Michael Board Member 1 0 X 0 0 0 Cason Len Board Member 1 0 X 0 0 0 Champlin Hiram Board Member 1 0 X 0 0 0 Collins Mark Board Member 1 0 X 0 0 0 Cox Rusty Board Member 1 0 X 0 0 0 Crawford Bill Board Member 1 0 X 0 0 0 Drake Ramsey Board Member 1 0 X 0 0 0 Duncan Walt Board Member 1 0 X 0 0 0 Eagan Claire Board Member 1 0 X 0 0 0 Edwards Carl Board Member 1 0 X 0 0 0 Evans Pat Board Member 1 0 X 0 0 0 Everest Christy Board Member 1 0 X 0 0 0 Felton Ann Board Member 1 0 X 0 0 0 Fergeson Ken Board Member 1 0 X 0 0 0 Ferree Larry Board Member 1 0 X 0 0 0 Fischer Malinda Board Member 1 0 X 0 0 0 Fretwell Barbara Board Member 1 0 X 0 0 0 Funke Mark Board Member 1 0 X 0 0 0 Gamble Gerald Board Member 1 0 X 0 0 0 Griffin John Board Member 1 0 X 0 0 0 Griffin Martha Board Member 1 0 X 0 0 0 Groendyke Virginia Board Member 1 0 X 0 0 0 Haglund Jacqui Board Member 1 0 X 0 0 0 Hall Brooks Board Member 1 0 X 0 0 0 Hargis Burns Board Member 1 0 X 0 0 0 Hawley Bill Board Member 1 0 X 0 0 0 Henry Kim Board Member 1 0 X 0 0 0 Henry Robert Board Member 1 0 X 0 0 0 Hogan Randy Board Member 1 0 X 0 0 0 Holmes Jerome Board Member 1 0 X 0 0 0 Hudson Cliff Board Member 1 0 X 0 0 0 Jameson Brett Board Member 1 0 X 0 0 0 Johnstone Bill Board Member 1 0 X 0 0 0 Kerr Lou Board Member 1 0 X 0 0 0 Levy Harrison Board Member 1 0 X 0 0 0 Little Dan Board Member 1 0 X 0 0 0 Loughridge Bill Board Member 1 0 X 0 0 0 McCarty Jack Board Member 1 0 X 0 0 0 McPherson Frank Board Member 1 0 X 0 0 0 Morris Jim Board Member 1 0 X 0 0 0 Mueller James Board Member 1 0 X 0 0 0 Nichols Larry Board Member 1 0 X 0 0 0 Parry Richard Board Member 1 0 X 0 0 0 Patten Rebecca Board Member 1 0 X 0 0 0 Payne Bond Board Member 1 0 X 0 0 0 Pierson Gary Board Member 1 0 X 0 0 0 Pitman Don Board Member 1 0 X 0 0 0 Rainbolt David Board Member 1 0 X 0 0 0 Replogle Dee Board Member 1 0 X 0 0 0 Rooney Pat Board Member 1 0 X 0 0 0 Ross Bob Board Member 1 0 X 0 0 0 Samis Mike Board Member 1 0 X 0 0 0 Saxon John Board Member 1 0 X 0 0 0 Schulte Paul Board Member 1 0 X 0 0 0 Stough Phyllis Board Member 1 0 X 0 0 0 Swimmer Ross Board Member 1 0 X 0 0 0 Switzer Becky Board Member 1 0 X 0 0 0 Taylor Steven Board Member 1 0 X 0 0 0 Thorpe Betsy Board Member 1 0 X 0 0 0 Walton Greg Board Member 1 0 X 0 0 0 Ward Lew Board Member 1 0 X 0 0 0 Williams Jr G Rainey Board Member 1 0 X 0 0 0 Wymer Deane Board Member 1 0 X 0 0 0 Prescott Stephen President and CEO 50 0 X 791848 0 258138 Paul Kincade VP of Research & Member, Immunobiology and Cancer 50 0 X 265644 0 36954 Morgan Chip Executive VP & Chief Operating Officer 50 0 X 222620 0 34019 Cohen Adam Sr VP & General Counsel 50 0 X 224074 0 32808 Voss Penny VP of Development 50 0 X 199143 0 56236 Kennedy Larry VP of Technology Transfer 50 0 X 162443 0 24755 Hassen Tim VP and CFO 50 0 X 206105 0 36583 Day Lisa VP of Business and Government Affairs 50 0 X 112508 0 17740 Courtney Stevens VP of Human Resources 50 0 X 104428 0 18222 James Judith Program Chair, Arthritis and Clinical Immunology 50 0 X 360847 0 47220 McEver Rodger Program Chair, Cardiovascular Biology 50 0 X 319231 0 39810 Pardo Gabriel Associate Member, Arthritis and Clinical Immunology 50 0 X 322517 0 41336 Husain Farhat Associate Member, Arthritis and Clinical Immunology 50 0 X 224594 0 34719 Gaffney Patrick Member, Arthritis and Clinical Immunology 50 0 X 236504 0 114075 Sivils Kathy Member, Arthiritis and Clinical Immunology 50 0 X 224523 0 39212 Tummala Saigiridhar Director of Comparative Medicine & Attending Vet 50 0 X 212612 0 37239 Capra J Donald Former President 10 0 X 172426 0 0 4362067 0 869066 47 1 1 0 Infusion Management LLC 11233 Shadow Creek Pkwy Pearland TX 77584 Medical Billing Services 2779556 Aramark 24863 Network Pl Chicago IL 606731248 HouseKeeping Services 490635 SAIC Energy Environment & Infastructure Rt 1 Box 223563 Pittsburgh PA 152512563 Architect 288486 Parker Highlander 1120 S Capital of Texas Hwy Bldg One Ste 200 Austin TX 78746 Legal 179245 5 142604 0 463531 0 36958093 18414140 959010 55978368 Clinical Revenue 621399 5774897 5774897 0 0 0 0 0 0 5774897 3325442 3325442 0 0 93436 93436 0 0 2530495 2530495 0 0 401597 0 0 0 401597 0 401597 401597 0 0 68564 676558 67445 1070521 1119 -393963 -392844 -392844 0 0 0 463531 0 0 0 0 Cafe Income 722100 257758 257758 0 0 Laboratory Income 541380 1498760 1498760 0 0 0 0 0 0 1756518 69467909 13489541 0 0 3168032 2244118 724771 199143 22520419 20729784 890280 900355 8205131 7090615 809173 305343 175660 120036 55624 99675 68112 31563 461192 0 461192 1253341 1253341 613761 399043 89971 124747 726155 630769 56517 38869 3549404 2784972 764017 415 653839 578178 53520 22141 91766 86799 2416 2551 2636360 2547729 88631 0 8668422 8240889 427533 0 474206 324045 150161 Lab Supplies 8121470 8119414 2056 0 Trainee Costs 1256692 1256692 0 0 Inhouse 2119182 2081174 25614 12394 Subcontracts 4712993 4712993 0 0 2052998 1627506 145681 279811 71560698 64896209 4778720 1885769 4300 4300 20254095 21875917 12181152 12604562 2035725 2813091 0 0 0 0 257777 349231 3392 4785 738369 401899 223620536 102356284 125898623 121264252 93587338 104370997 1182212 1737938 0 0 0 0 123353956 136422046 379496939 401849018 6579010 7006902 0 0 0 0 51933612 50933440 3423360 3973258 61935982 61913600 X 111634660 113170541 33262896 40602185 172663401 186162692 317560957 339935418 379496939 401849018 X -2092789 0 0 0 0 24467250 X 0 1 X 1 1 1 X 69877368 69070646 56883620 51804565 55978368 303614567 0 0 0 0 0 0 0 0 0 0 0 0 69877368 69070646 56883620 51804565 55978368 303614567 10918016 292696551 7117954 6803393 6055949 6515711 7714644 34207651 0 0 0 0 0 0 0 0 0 0 0 0 337822218 5774897 0.86642 0.90106 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 0 1 0 0 0 0 1 461192 0 0 461192 0 Schedule C, Part II-B, Line 1 The Foundation's lobbying activities entail monitoring proposed legislation and educating legislators and their staffs about the Foundation, medical research and the impact of proposed legislation on medical research and the Foundation. 76260090 390308 12952162 0 3300000 0 86302560 66735078 3205030 9519982 0 3200000 0 76260090 69793689 76613 64776 0 3200000 0 66735078 58867420 237181 13989088 0 3300000 0 69793689 58951820 239636 2975964 0 3300000 0 58867420 0.0758 0.6141 0.3101 1 0 3944520 0 3944520 179828279 0 72968694 106859585 0 0 0 0 39842386 0 29387590 10454796 5351 0 0 5351 121264252 Funds Held in Trust by Others 132447670 Wills & Bequests, Net 2274403 Cash Surrender Value of Life Insurance 959729 Debt Issue Costs 381941 Deposits 164050 Accrued Interest Receivable 146177 Assets Held for Sale 47970 Minerals 106 136422046 Split Interest Agreements & Other Liabilities 452128 Postretirement Benefits & Deferred Compensation 3521130 3973258 X 69467909 0 0 0 0 0 69467909 0 0 0 69467909 71560698 0 0 0 0 0 71560698 0 0 0 71560698 Schedule D, Part V, Line 4 The Foundation's endowment consists of individual funds established to provide the Foundation with funding in perpetuity. Schedule D, Part X, Line 2 Management has reviewed the Foundation's tax positions and concluded that there are no uncertain tax positions that require accrual in the financial statements or disclosure in the footnotes to be in compliance with authoritative literature. Generally, the Foundation is no longer subject to income tax examination by federal, state or local tax authorities for years prior to 2011. 241 Event 675951 100000 575951 0 779 0 5681 37922 68038 0 0 675951 100000 575951 0 779 0 5681 37922 68038 112420 463531 X 1 1 X X X X X X 0 1 0 0 0 0 0 1 0 Prescott Stephen President and CEO 763451 0 1524 0 26873 0 248269 0 9143 0 1049260 0 0 0 Paul Kincade VP of Research & Member, Immunobiology and Cancer 237106 0 3225 0 25313 0 27769 0 9185 0 302598 0 0 0 Morgan Chip Executive VP & Chief Operating Officer 196845 0 0 0 25775 0 24877 0 9143 0 256640 0 0 0 Cohen Adam Sr VP & General Counsel 204617 0 100 0 19357 0 25029 0 7779 0 256882 0 0 0 Voss Penny VP of Development 179994 0 75 0 19074 0 41848 0 14388 0 255379 0 0 0 Kennedy Larry VP of Technology Transfer 157388 0 0 0 5055 0 15612 0 9143 0 187198 0 0 0 Hassen Tim VP and CFO 204728 0 0 0 1377 0 22974 0 13609 0 242688 0 0 0 Day Lisa VP of Business and Government Affairs 108608 0 0 0 3900 0 9483 0 8257 0 130248 0 0 0 Courtney Stevens VP of Human Resources 103138 0 0 0 1289 0 8590 0 9632 0 122649 0 0 0 James Judith Program Chair, Arthritis and Clinical Immunology 338840 0 3000 0 19007 0 38620 0 8600 0 408067 0 0 0 McEver Rodger Program Chair, Cardiovascular Biology 290498 0 3100 0 25633 0 27769 0 9143 0 356143 0 0 0 Pardo Gabriel Associate Member, Arthritis and Clinical Immunology 322076 0 0 0 441 0 27769 0 13567 0 363853 0 0 0 Husain Farhat Associate Member, Arthritis and Clinical Immunology 223826 0 0 0 768 0 24755 0 9964 0 259313 0 0 0 Gaffney Patrick Member, Arthritis and Clinical Immunology 212428 0 10075 0 14001 0 100509 0 13567 0 350580 0 0 0 Sivils Kathy Member, Arthiritis and Clinical Immunology 223038 0 75 0 1410 0 24824 0 14388 0 263735 0 0 0 Tummala Saigiridhar Director of Comparative Medicine & Attending Vet 194370 0 0 0 18242 0 22974 0 14265 0 249851 0 0 0 Schedule J, Part I, Line 1a First class travel is allowed for the CEO to allow him to accomplish work related tasks while traveling. Schedule J, Part I, Line 3 Compensation for the CEO is determined by leadership of the board of directors based on comparability data from widely accepted peer benchmarking surveys that are segmented by region and size of entity. Schedule J, Part I, Line 4 The Board of the Foundation periodically uses nonqualified retirement plans as a retention tool. Schedule J, Part I, Line 7 The CEO receives an annual bonus that is determined by leadership of the board of directors based on performance. The bonus is considered as a portion of total compensation and is subject to the review process previously described. A Oklahoma Industries Authority 736194355 679103YC9 2008-08-14 42955000 Revenue Bonds (OMRF Project) Series 2008 0 0 0 B Oklahoma Industries Authority 736194355 XXNONEXXX 2010-05-26 12185000 Revenue Bonds (OMRF Project) Series 2010 0 0 0 A 5010000 0 43457720 3316750 0 0 141976 0 0 30540129 0 9428809 2011 0 0 0 1 B 0 0 12320300 1218339 0 0 138825 0 0 0 10963136 0 2011 0 1 1 1 A 0 0 0 1 1 0 0 0 1 0 1 B 0 0 0 1 1 0 0 0 1 0 1 A 0 0 0 1 0 0 0 1 1 B 1 0 0 0 0 1 A 1 B 1 Schedule K, Part IV, Line 2c-08/14/2008 42,955,000 Oklahoma Industries Authority No rebate was due according to the rebate calculated November 21, 2013 for the rebate period beginning May 26, 2010 through June 30, 2013. Accele Biopharm Common Directors 200000 Equity investment 0 Accele Venture Partners Common Directors 152389 Equity investment 0 Bank of Oklahoma Common Directors 110016 Investment and mineral asset management 0 Ginny Bass Carl Related to Board Member 95000 Payroll 0 Peter Carl Related to Board member 53685 Payroll 0 Presbyterian Health Foundation Common Directors 35728 Rental expense for building space 0 McAfee & Taft Common Directors 33025 Legal services 0 X 16 59010 FMV X 1 900000 FMV 1 0 1 1 Schedule M, Part I, Line 32b A third party is used to sell gifts of stocks or bonds received from donors. Usually the donor transfers the stocks directly from their brokerage account into OMRF's third party account. Occasionally, OMRF receives stock certificates and those are sent directly to the third party to process. Form 990, Part VI, Section A, Line 1a The Foundation's Board of Directors has delegated all of its powers to the Foundation's Executive Committee, except as follows: establish the overall policies and direction of the Foundation, appoint the members of the Executive Committee, elect and remove the Chair of the Board of Directors, amend the Bylaws and the Certificate of Incorporation of the Foundation, and appoint special committees to the Board of Directors. The Board of Directors may at any time amend or revoke this delegation of powers. Form 990, Part VI, Section A, Line 2 The Foundation currently has 87 directors, many of whom are business leaders and members of prominent families in the State of Oklahoma. The Foundation believes there are multiple business relationships between and among board members and families of Board members, but the Foundation review of signed conflict of interest disclosures from all board members and of the Foundation's ledger accounts indicated there are no such relationships that would impair the fiduciary duties of any director to the Foundation. Form 990, Part VI, Section B, Line 11b A summary of the Form 990 is presented for review to the Executive Committee. Subsequent to that review, the Form 990 with all supplemental schedules is made available to all members of the board of directors for review and comment prior to filing. Form 990, Part VI, Section B, Line 12c Each director, officer and key employee is annually provided with a copy of the Foundation's conflict of interest policy. Each of these individuals is annually provided with a questionnaire regarding potential conflicts and required to disclose any potential conflict that he or she might have. In addition, each of these individuals must annually sign a statement affirming that he or she has; received a copy of the conflicts of interest policy, read and understood the policy and agrees to comply with the policy. Once the Foundation has collected annual disclosure statements from all directors, officer and key employees, the Foundation's Governance Committee reviews such information to identify situations in which a potential conflict exists and is material. If a potential material conflict is identified, the committee analyzes whether the contemplated transaction may be authorized as just, fair, and reasonable to the Foundation. The Governance Committee then makes a recommendation to the Foundations' Executive Committee regarding the management of all potential conflicts it has identified. The final decision as to the approval and , where applicable, management of all such potential conflicts rests in the sole discretion of the Executive Committee, which makes such decisions based upon the welfare of the Foundation and the advancement of its purpose. The recommendations of the Governance Committee and decisions of the Executive Committee are documented in the respective minutes of these Committees' regular meetings. Form 990, Part VI, Section B, Line 15 Compensation for officers and key employees is determined and evaluated in May of each year by the executive committee of the board of directors based on comparability data from widely accepted peer benchmarking salary surveys that are segmented by region and size of entity. Form 990, Part VI, Section C, Line 19 The Foundation's governing documents, conflicts of interest policy, and financial statements are provided upon request and are publicly available on the Foundation's website. Form 990, Part XI, Line 9 Includes increase (decrease) in fair value of funds held in trust by others, net investment losses in excess of gains (losses) designated for operations and pension related changes other than net periodic pension costs.